Latest Boston Scientific News

Page 1 of 1
Boston Scientific has priced US$3 billion and €4.25 billion of senior notes to help fund its proposed acquisition of Penumbra. The debt carries a range of maturities and includes special redemption terms if the transaction fails to close.
Ada Torres
Ada Torres
21 Nov 2026
Cochlear has reaffirmed FY27 underlying net profit guidance of $330 million to $350 million after a disappointing FY26, while pointing to strong Nexa adoption and progress on fully implantable hearing technology. The company is cutting fixed costs and expanding medical referral pathways as it seeks to convert a large pool of untreated adult hearing loss into growth.
Victor Sage
Victor Sage
26 Oct 2026
Marlin Global’s portfolio fell 6.3% before fees and tax in FY26 while its benchmark gained 30.5%, producing a NZ$17.3 million net loss. The Fisher Funds-managed vehicle is responding with broader sector coverage, faster portfolio turnover and an expanded research team.
Victor Sage
Victor Sage
28 Sept 2026
Marlin Global's portfolio delivered a 2.0% gross return in Q2 2026, driven by rebounds in ICON and semiconductor holdings, but lagged a strong US market rally led by AI and chip stocks.
Victor Sage
Victor Sage
20 July 2026
Marlin Global’s portfolio lagged the broader market in May 2026, weighed down by semiconductor underexposure and near-term revenue challenges in key holdings, while AI-focused stocks powered a narrow rally.
Claire Turing
Claire Turing
12 June 2026
Marlin Global delivered a 4.0% gross portfolio return in April 2026, driven by strong gains in AI-focused tech stocks like Amazon and Alphabet. However, its cautious stance on semiconductors limited upside amid a sector rally.
Claire Turing
Claire Turing
13 May 2026

Browse the archive

Full archive